

Andrew Collier, MRCP  
Alan W. Patrick, MRCP  
Derek Bell, MRCP  
David M. Matthews, MRCP  
Cecilia C.A. MacIntyre, MSc  
David J. Ewing, FRCP  
Basil F. Clarke, FRCP

# Relationship of Skin Thickness to Duration of Diabetes, Glycemic Control, and Diabetic Complications in Male IDDM Patients

Skin thickness is primarily determined by collagen content and is increased in insulin-dependent diabetes mellitus (IDDM). We measured skin thickness in 66 IDDM patients aged 24–38 yr and investigated whether it correlated with long-term glycemic control and the presence of certain diabetic complications. With univariate analysis, skin thickness was increased and significantly related to duration of diabetes ( $P < .001$ ), previous glycemic control ( $P < .001$ ), retinopathy ( $P < .001$ ), cheiroarthropathy ( $P < .001$ ), and vibration-perception threshold ( $P < .05$ ). There was a negative correlation between forced expiratory volume at 1 s ( $P < .05$ ) and vital capacity ( $P < .05$ ) with duration of diabetes. Neither skin thickness nor ankle arteriomedial wall calcification correlated with abnormal autonomic function tests. When corrected for duration of diabetes, there was a weak correlation between skin thickness and glycemic control ( $P < .05$ ) but no correlation with retinopathy, cheiroarthropathy, and vibration-perception threshold. This study confirms that there are widespread connective tissue changes in diabetes mellitus, although the biochemistry needs further elucidation. *Diabetes Care* 12:309–12, 1989

**D**iabetes mellitus is accompanied by widespread biochemical, morphological, and functional abnormalities of collagen and elastin (1–3). Nonenzymatic glycosylation (NEG), involving various proteins, occurs in diabetes, and glycosylated hemoglobin and glycosylated serum proteins are rou-

tinely used as indices of glycemic control (3–5). Collagen is the most studied protein regarding advanced NEG, because of the ease with which it can be examined in skin biopsies, and because of its importance as a protein that is present in several tissues subject to complications in diabetes, e.g., vascular basement membrane, arterial wall, and lung (6–10).

Skin thickness (epidermal surface to dermal fat interface), which is primarily determined by collagen content, is greater in insulin-dependent diabetes mellitus (IDDM) patients who have been diabetic for  $>10$  yr (11,12). This possibly reflects increased collagen cross-linkage and reduced collagen turnover (2,3).

The aims of this study were to investigate whether the increase in skin thickness related to long-term glycemic control and correlated with microangiopathic complications, cheiroarthropathy, and abnormalities in respiratory and autonomic function.

## MATERIALS AND METHODS

**Subjects.** Sixty-six male IDDM patients routinely attending the clinic (mean  $\pm$  SD age  $32.6 \pm 2.8$  yr [range 24–38 yr] and mean duration of diabetes  $13.0 \pm 7.3$  yr [range 1–29 yr]) and 21 healthy male volunteers of comparable age ( $30.1 \pm 2.8$  yr, range 26–36 yr) took part in the study. Retinopathy was assessed ophthalmoscopically after mydriasis. Thirty-one (47%) had no retinopathy, whereas 18 (27%) had background changes, 5 (8%) had exudative retinopathy, and 12 (18%) had proliferative retinopathy. All patients had palpable peripheral pulses. None had plasma creatinine levels  $>130$   $\mu$ M, but 10 diabetic patients' urine tested Albustix positive. Ankle arteriomedial wall calcification was assessed by X ray with a standard lateral view and was

From the Diabetic and Dietetic Department, University Department of Medicine, Royal Infirmary, and the Medical Statistics Unit, University of Edinburgh, Edinburgh, Scotland, United Kingdom.

Address correspondence and reprint requests to A. Collier, MRCP, Level 7, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK.

graded as either positive or negative (13). Nineteen patients (28%) and 1 control subject had ankle arterio-medial wall calcification.

Glycemic control was assessed by glycosylated hemoglobin (HbA<sub>1c</sub>) measured by electrophoresis with commercially available agar plates, the normal range being 6–8% (14). The mean of at least 12 HbA<sub>1c</sub> results from the routine clinic visits over the previous 4 yr allowed retrospective analysis of glycemic control.

Skin thickness (epidermal surface to dermal fat interface) was measured with an ultrasound A scan system (Dermal depth detector, Cotech, Slough, UK) (15–16). Skin sites measured were the flexor surfaces of both forearms (10 cm proximal to the wrist crease), the medial aspects of the upper arms (10 cm proximal to the antecubital fossa), and the middorsal area of both feet.

Limited joint mobility, as a measure of cheiroarthropathy, was evaluated by the prayer maneuver described by Rosenbloom et al. (17). Of the 66 diabetic patients, 25 (38%) had mild cheiroarthropathy, 6 (9%) had moderate, and none had severe cheiroarthropathy. The findings were confirmed by two examiners.

Vital capacity (VC) and forced expiratory volume at 1 s (FEV<sub>1</sub>) were measured with a bellows spirometer (Vitalograph modal S, Maids Morton, Bucks, UK). The highest value for each volume from three maneuvers was taken (18). All subjects had an FEV<sub>1</sub>-VC ratio >75% at the time of the study, and none had a history of atopy or recent respiratory tract infection. Because of the possible confusing effects of smoking, smokers and ex-smokers were excluded from this part of the study, leaving data from 38 diabetic patients and 19 control subjects for analysis (10,19). Venous carboxyhemoglobin measured (IL 282 Co-Oximeter) at the time of study was <1% in all nonsmokers.

A standard battery of five cardiovascular autonomic nerve function tests (i.e., heart-rate responses to Valsalva's maneuver, deep breathing, and standing up and blood pressure responses to standing up and sustained hand grip) was performed and graded as previously described (20). Twelve diabetic patients did not undergo Valsalva's maneuver because of retinopathy, and in 1 diabetic patient no heart-rate tests were performed because of an arrhythmia. Pupil cycle time (PCT) was measured by timing 100 successive pupil oscillations induced by a slit-lamp beam (21). It was not possible to induce pupil cycling in 7 diabetic subjects. Vibration-perception threshold was measured with a standard technique as an assessment of large nerve fiber involvement (22).

Informed consent was obtained from each participant, and the protocol was approved by the local hospital advisory ethical committee.

**Statistical analysis.** Results are expressed as means  $\pm$  SD or median (range) as appropriate. Student's *t* test or  $\chi^2$ -tests were used for comparison between control and diabetic groups, and multiple linear regression was used to investigate the relationship between skin thickness (the dependent variable) and other factors. With regres-

sion analysis, patients were categorized into groups depending on whether they had indications of various complications (i.e., retinopathy, cheiroarthropathy, ankle arterio-medial wall calcification, and neuropathy). The Mann-Whitney test was used to compare PCT in diabetic and control subjects because in some diabetic individuals the pupils did not cycle, and therefore it was not possible to record a value.

## RESULTS

Skin thickness was greater in diabetic patients than in control subjects at all sites tested (Table 1). FEV<sub>1</sub> (4.0  $\pm$  0.5 vs. 4.5  $\pm$  0.61, *P* < .005) and VC (4.9  $\pm$  0.7 vs. 5.4  $\pm$  0.91, *P* < .05) were reduced in the 38 non-smoking diabetic patients when compared with control subjects. However, there was no detectable difference in the FEV<sub>1</sub>-VC (82.2  $\pm$  6.3 vs. 83.4  $\pm$  5.8%) ratio between the two groups. Fifty-six patients (85%) had normal cardiovascular autonomic function tests, whereas 6 (9%) had early abnormalities and 4 (6%) had severe changes. There was no statistical difference in PCT between diabetic and control groups (median 1000 vs. 960 s). The diabetic group, however, had increased vibration-perception thresholds in both the upper (4.6  $\pm$  1.7 vs. 2.9  $\pm$  0.6 U, *P* < .0001) and lower (9.2  $\pm$  5.5 vs. 5.6  $\pm$  2.3 U, *P* < .005) limbs.

With univariate analysis, skin thickness was correlated with duration of diabetes (*r* = .53, *P* < .001), previous glycemic control (*r* = .36, *P* < .001), retinopathy (*P* < .001), ankle arterio-medial wall calcification (*P* < .001), cheiroarthropathy (*P* < .001), and vibration-perception threshold (*P* < .05). There were too few patients with clinical nephropathy for this to be included in the statistical analysis. There was a negative correlation between FEV<sub>1</sub> (*r* = -.27, *P* < .05) and VC (*r* = -.26, *P* < .05) and duration of diabetes. There was no significant relationship between skin thickness and auto-

**TABLE 1**  
Skin thickness at different sites in arms and legs in diabetic and control subjects

Site	Groups	
	Diabetic	Control
<i>n</i>	66	21
Upper arm		
L	1.19 $\pm$ 0.24	0.96 $\pm$ 0.09
R	1.21 $\pm$ 0.25	0.97 $\pm$ 0.16
Forearm		
L	1.19 $\pm$ 0.17	0.96 $\pm$ 0.10
R	1.16 $\pm$ 0.21	0.98 $\pm$ 0.12
Foot		
L	1.53 $\pm$ 0.28	1.31 $\pm$ 0.22
R	1.52 $\pm$ 0.27	1.25 $\pm$ 0.20

Results are expressed as means  $\pm$  SD in millimeters. *P* < .001 for all comparisons.

onomic neuropathy or between abnormal autonomic tests and ankle arteriomedial wall calcification. When duration of diabetes was taken into account with multiple regression analysis, there was a weak but significant correlation between skin thickness and previous glycemic control (partial correlation coefficient 0.29,  $P < .05$ ). Although after correction for duration of diabetes skin thickness was not correlated with retinopathy, ankle arteriomedial wall calcification, or cheiroarthropathy, these factors were strongly associated with duration of disease ( $P < .001$ ). When the group of patients with duration of diabetes  $>15$  yr ( $n = 30$ ) was analyzed separately, there was a significant correlation between skin thickness and HbA<sub>1c</sub> (partial correlation coefficient 0.54,  $P < .01$ ). However, in this subset there was an insufficient number of patients without retinopathy, ankle arteriomedial wall calcification, or cheiroarthropathy to assess the correlation between these parameters and skin thickness.

## DISCUSSION

This study confirms that skin thickness is increased in IDDM patients and correlates with both duration of diabetes and glycemic control (12,23). After correction for duration of diabetes, there was no correlation between skin thickness and the diabetic complications assessed. However, the presence of these complications, including reduced FEV<sub>1</sub> and VC, correlated with duration of diabetes. Only a few patients had significant abnormalities in cardiovascular autonomic function tests, but because of the limitation of the small numbers with abnormalities, we found no correlation between autonomic function abnormalities and ankle arteriomedial wall calcification. This reinforces our previous clinical impressions and does not confirm a recent study (13).

There appear to be two possible pathophysiological mechanisms by which hyperglycemia leads to irreversible tissue damage. A major consequence of hyperglycemia is excessive NEG of proteins (2,3). The initial step in NEG is rapid and reversible and results in the formation of a Schiff base. This is followed by a slow rearrangement to a more stable ketoamine linkage (the Amadori rearrangement). With further reactions and rearrangements beyond the Amadori product, advanced glycosylation end-products accumulate causing increased cross-linkage of collagen, appearance of brown fluorescent pigments, decreased susceptibility to *in vivo* and *in vitro* proteolysis, increased stiffness, and thermal stability (24–27). Collagen browning is more intense in patients with more severe retinopathy, arterial wall stiffness, and joint stiffness (25). The exact role of browning in the etiology of diabetic complications remains unknown, and it may simply reflect duration and severity of hyperglycemia (28–30).

Another consequence of hyperglycemia is that it can induce altered steady-state levels of intracellular metab-

olites. The polyol pathway has been implicated in the pathogenesis of peripheral neuropathy and acute diabetic cataracts (31,32). Increased polyol pathway activity results in decreased levels of NADPH, glutathione, and *myo*-inositol (32). In addition, polyol accumulation is associated with increased collagen hydration and stiffness of connective tissue (33,34).

Collagen determines skin thickness and is the most abundant protein in the body (11). The increase in skin thickness occurring in association with diabetic complications may indicate that there is a common etiological link in their development or possibly that both are time-dependent processes. Although additional investigation is required into the biochemistry of NEG and the polyol pathway and the links between these processes and the development of diabetic complications, this study provides further insight into the widespread changes in connective tissue in patients with diabetes mellitus.

## ACKNOWLEDGMENTS

We are grateful to C. Mackay for secretarial assistance. D.J.E. is a Wellcome Trust Senior Lecturer.

## REFERENCES

1. Sternberg M, Cohen-Fortere L, Peyroux J: Connective tissue in diabetes mellitus: biochemical alterations of the intercellular matrix with special reference to proteoglycans, collagens and basement membranes. *Diabete Metab* 11:27–50, 1985
2. Brownlee M, Vlassara H, Cermai A: Non-enzymatic glycosylation and the pathogenesis of diabetic complications. *Ann Intern Med* 101:527–37, 1984
3. Kennedy L, Baynes JW: Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. *Diabetologia* 26:93–98, 1984
4. Goldstein DE, Parker KM, England JD, England JE Jr, Weidmeyer H-M, Rawlings SS, Hess R, Little RR, Simonds JF, Breyfogle RP: Clinical application of glycosylated hemoglobin measurements. *Diabetes* 31 (Suppl. 3):70–78, 1982
5. Baker JR, Metcalf PA, Holdaway IM, Johnson RN: Serum fructosamine concentration as a measure of blood glucose control in type 1 (insulin-dependent) diabetes mellitus. *Br Med J* 290:352–55, 1985
6. Williamson JR, Kilo C: Capillary basement membranes in diabetes. *Diabetes* 32 (Suppl. 2):96–100, 1983
7. Pillsbury HC, Hung L, Kyte MC, Fries EDL: Arterial pulse waves and velocity and systolic time intervals in diabetic children. *Am Heart J* 87:783–90, 1974
8. Jarrett RJ, Keen H, Chakrabarti R: Diabetes, hyperglycaemia and arterial disease. In *Complications of Diabetes*. 2nd ed. Keen H, Harret RJ, Eds. London, Arnold, 1982, p. 179–203
9. Schuyler A, Niewoehner DE, Inkley SR, Kohn RR: Abnormal lung elasticity in juvenile diabetes mellitus. *Am Rev Respir Dis* 113:37–41, 1976

10. Bell D, Collier A, Matthews DM, Cooksey EJ, McHardy GJR, Clarke BF: Are reduced lung volumes in IDDM due to defect in connective tissue? *Diabetes* 37:829–31, 1988
11. Schuster S, Black NM, McVitie E: The influence of age and sex on skin thickness: skin collagen and density. *Br J Dermatol* 93:639–43, 1975
12. Collier A, Matthews DM, Kellett HA, Clarke BF, Hunter JA: Change in skin thickness associated with cheiroarthropathy in insulin-dependent diabetes mellitus. *Br Med J* 292:936, 1986
13. Edmonds ME, Morrison N, Laws JW, Watkins PJ: Medial arterial calcification in diabetic neuropathy. *Br Med J* 284:928–30, 1982
14. Read A, Tibi L, Smith AF: Assessment of a simple method for measuring HbA<sub>1c</sub>. *Clin Chim Acta* 108:487–91, 1980
15. Alexander H, Miller DL: Determining skin thickness with pulsed ultrasound. *J Invest Dermatol* 72:17–19, 1979
16. Tan CY, Statham B, Marks R, Payne PA: Skin thickness measurement by pulsed ultrasound: its reproducibility, validation and variability. *Br J Dermatol* 106:657–67, 1982
17. Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K, McCallum M: Limited joint mobility in childhood diabetes mellitus indicates increased risk of microvascular disease. *N Engl J Med* 305:191–94, 1981
18. Crapo RO, Morris AH, Clayton PD, Nixon CR: Lung volumes in healthy non-smoking adults. *Bull Eur Physiol Pathol Respir* 18:419–25, 1982
19. Krumholz RA, Hedrick EC: Pulmonary function differences in normal smoking and non-smoking middle aged white collar workers. *Am Rev Respir Dis* 107:225–30, 1973
20. Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care* 8:491–98, 1985
21. Martyn CN, Ewing DJ: Pupil cycle time: a simple way of measuring an autonomic reflex. *J Neurol Neurosurg Psychiatry* 49:771–74, 1986
22. Martyn CN, Reid W, Young RJ, Ewing DJ, Clarke BF: Six-month treatment with sorbinil in asymptomatic diabetic neuropathy: failure to improve abnormal nerve function. *Diabetes* 36:987–90, 1987
23. Rosenbloom AL, Frias JL: Diabetes, short-stature and joint stiffness: a new syndrome (Abstract). *Clin Res* 22:92A, 1974
24. Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. *Proc Natl Acad Sci USA* 81:583–87, 1984
25. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type 1 diabetes mellitus and collagen linked fluorescence. *N Engl J Med* 314:403–408, 1986
26. Lubec G, Pollak A: Reduced susceptibility of non-enzymatically glycosylated glomerular basement to proteases. *Renal Physiol* 3:4–8, 1980
27. Andreassen T, Seyer-Hassen K, Bailey AJ: Thermal stability, mechanical properties and reducible cross-links of rat tail lesions in experimental diabetes. *Biochim Biophys Acta* 677:312–17, 1981
28. Browning and diabetic complications. *Lancet* 1:1192–93, 1986
29. Pirart J: Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. *Diabetes Care* 1:168–88, 1978
30. Tchobroutsky G: Relation of diabetic control to development of microvascular complications. *Diabetologia* 15:143–52, 1978
31. Green DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides and sodium-potassium ATPase in the pathogenesis of diabetic complications. *N Engl J Med* 316:599–606, 1987
32. Stribling D, Perkins CM: Aldose reductase inhibitor. In *Recent Advances in Diabetes*. 2. Nattrass M, Ed. Edinburgh, Churchill Livingstone, 1986, p. 169–76
33. Eaton RP, Sibbitt WL, Harsh A: The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetes mellitus. *JAMA* 253:1437–41, 1985
34. Eaton RP: The collagen hydration hypothesis: a new paradigm for the secondary complications of diabetes mellitus. *J Chronic Dis* 39:763–66, 1986